Conditions: Hepatic Insufficiency
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 37
Healthy volunteers: yes

Brief summary:
This study will explore how liver impairment affects blood levels of LY2140023 (a prodrug) and its active metabolite (LY404039).

Detailed description:
The study included 4 groups, based on the Child-Pugh classification of hepatic impairment as follows:

Group 1: Participants with normal hepatic function (Control); Group 2: Participants with mild hepatic impairment (Child-Pugh class A); Group 3: Participants with moderate hepatic impairment (Child-Pugh class B); and Group 4: Participants with severe hepatic impairment (Child-Pugh class C).

Arms:
arm 1: A single oral dose of 80 milligrams (mg) LY2140023 administered on Day 1.

Interventions: intervention 1: LY2140023
Intervention descriptions: intervention 1: None

Protocol document: